Anti-viral compositions and methods of use thereof

An anti-viral composition comprising:

• from about 0.01% to about 5.0% w/v zinc;
• from about 0.001% to about 0.1% w/v of an alpha-adrenergic receptor agonist;
• from about 1% to about 5% w/v of one or more nonionic surfactants;
• from about 0.1% to about 5% w/v of one or more viscosity enhancers;
• from about 0.01% to about 0.1% w/v of one or more antioxidants;
• from about 0.01% to about 0.5% w/v of one or more preservatives;
• from about 0.01% to about 0.1% w/v of L-cysteine;
• from about 0.01% to about 0.1% w/v of N-acetyl cysteine;
• from about 4.0 to about 10.0 millimolar of a buffer;
• and
• optionally, from about 0.05% to about 0.25% w/v of a sorbate,
• wherein w/v denotes weight by total volume of the composition.

An anti-viral composition comprising:

• from about 0.001% to about 0.5% w/v oxymetazoline,
• from about 0.01% to about 5.0% w/v of a zinc salt;
• from about 1.25% to about 4.0% w/v of a polysorbate;
• from about 1% to about 5% w/v of one or more polyols;
• from about 0.1% to about 5% w/v of one or more viscosity enhancers;
• from about 0.1% to about 2% w/v sodium chloride;
• from about 1.0 to about 5.0 mM of one or more buffers, wherein the composition has a pH from about 4.5 to about 8.0.